title: Subthalamic nucleus stimulation affects orbitofrontal cortex in facial emotion recognition: a PET study.
abstract: Deep brain stimulation (DBS) of the bilateral subthalamic nucleus (STN) in Parkinson's disease is thought to produce adverse events such as emotional disorders, and in a recent study, we found fear recognition to be impaired as a result. These changes have been attributed to disturbance of the STN's limbic territory and would appear to confirm that the negative emotion recognition network passes through the STN. In addition, it is now widely acknowledged that damage to the orbitofrontal cortex (OFC), especially the right side, can result in impaired recognition of facial emotions (RFE). In this context, we hypothesized that this reduced recognition of fear is correlated with modifications in the cerebral glucose metabolism of the right OFC. The objective of the present study was first, to reinforce our previous results by demonstrating reduced fear recognition in our Parkinson's disease patient group following STN DBS and, second, to correlate these emotional performances with glucose metabolism using (18)FDG-PET. The (18)FDG-PET and RFE tasks were both performed by a cohort of 13 Parkinson's disease patients 3 months before and 3 months after surgery for STN DBS. As predicted, we observed a significant reduction in fear recognition following surgery and obtained a positive correlation between these neuropsychological results and changes in glucose metabolism, especially in the right OFC. These results confirm the role of the STN as a key basal ganglia structure in limbic circuits.
authors.affiliation: Service de Médecine Nucléaire, Centre Eugène Marquis, rue de la Bataille Flandres Dunkerque, 35042 Rennes, France.
authors.forename: F
authors.initials: F
authors.lastname: Le Jeune
authors.forename: J
authors.initials: J
authors.lastname: Péron
authors.forename: I
authors.initials: I
authors.lastname: Biseul
authors.forename: S
authors.initials: S
authors.lastname: Fournier
authors.forename: P
authors.initials: P
authors.lastname: Sauleau
authors.forename: S
authors.initials: S
authors.lastname: Drapier
authors.forename: C
authors.initials: C
authors.lastname: Haegelen
authors.forename: D
authors.initials: D
authors.lastname: Drapier
authors.forename: B
authors.initials: B
authors.lastname: Millet
authors.forename: E
authors.initials: E
authors.lastname: Garin
authors.forename: J-Y
authors.initials: JY
authors.lastname: Herry
authors.forename: C-H
authors.initials: CH
authors.lastname: Malbert
authors.forename: M
authors.initials: M
authors.lastname: Vérin
mesh_terms: D016022:Case-Control Studies; D046690:Deep Brain Stimulation / Q000009:adverse effects* / Q000379:methods; D005149:Facial Expression; D005239:Fear; D005260:Female; D019788:Fluorodeoxyglucose F18; D005625:Frontal Lobe / Q000000981:diagnostic imaging* / Q000502:physiology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000378:metabolism / Q000523:psychology / Q000628:therapy*; D049268:Positron-Emission Tomography; D021641:Recognition, Psychology; D018709:Statistics, Nonparametric; D020531:Subthalamic Nucleus / Q000000981:diagnostic imaging* / Q000502:physiology
chemical_list: D019788:Fluorodeoxyglucose F18; D005947:Glucose